BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
41.73
+1.73 (4.32%)
At close: Jun 20, 2025, 4:00 PM
41.69
-0.04 (-0.10%)
After-hours: Jun 20, 2025, 7:57 PM EDT
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 13 analysts that cover BridgeBio Pharma stock have a consensus rating of "Strong Buy" and an average price target of $56.67, which forecasts a 35.8% increase in the stock price over the next year. The lowest target is $45 and the highest is $95.
Price Target: $56.67 (+35.8%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 6 | 6 | 6 | 6 | 6 | 7 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 12 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $49 | Buy | Initiates | $49 | +17.42% | Jun 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $53 → $56 | Strong Buy | Maintains | $53 → $56 | +34.20% | Jun 9, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $52 → $55 | Buy | Maintains | $52 → $55 | +31.80% | Apr 30, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $46 → $63 | Buy | Maintains | $46 → $63 | +50.97% | Apr 30, 2025 |
| UBS | UBS | Strong Buy Maintains $65 → $72 | Strong Buy | Maintains | $65 → $72 | +72.54% | Apr 30, 2025 |
Financial Forecast
Revenue This Year
448.36M
from 221.90M
Increased by 102.05%
Revenue Next Year
693.56M
from 448.36M
Increased by 54.69%
EPS This Year
-3.17
from -2.88
EPS Next Year
-2.05
from -3.17
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 699.3M | 948.9M | 1.8B | ||
| Avg | 448.4M | 693.6M | 1.3B | ||
| Low | 300.4M | 362.9M | 569.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 215.1% | 111.6% | 154.2% | ||
| Avg | 102.1% | 54.7% | 81.4% | ||
| Low | 35.4% | -19.1% | -17.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.46 | -1.28 | 1.85 | ||
| Avg | -3.17 | -2.05 | 0.04 | ||
| Low | -3.85 | -3.25 | -1.96 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.